BSLN — Basilea Pharmaceutica AG Allschwil Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Market Cap
CH₣521.16m
Enterprise Value
CH₣496.36m
Revenue
CH₣208.54m

Annual income statement for Basilea Pharmaceutica AG Allschwil, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	128	148	148	158	209
Cost of Revenue
Gross Profit	104	124	123	131	170
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	136	147	129	138	147
Operating Profit	-8.54	0.69	18.5	19.2	61.2
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-14.7	-6.79	12.1	10.5	60.3
Provision for Income Taxes
Net Income After Taxes	-14.7	-6.83	12.1	10.5	77.6
Net Income Before Extraordinary Items
Net Income	-14.7	-6.83	12.1	10.5	77.6
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-14.7	-6.83	12.1	10.5	77.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-2.36	-0.558	1.03	0.872	5.6
Dividends per Share